REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Preparations Characterized By Special Physical Form > Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Capsules (e.g., Of Gelatin, Of Chocolate, Etc.)Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178148 - Preparations of growth hormone The present invention relates to compositions and systems for expressing pharmaceutically active gene products in plants. In particular, the invention provides compositions, systems and methods for the production of human growth hormone in plants. Provided are nucleic acid and protein sequences, expression and vector constructs, host cells and plants capable ... 07/26/07 - 20070172521 - Levetiracetam formulations and methods for their manufacture Substantially glidant free levetiracetam compositions, pharmaceutical compositions incorporating substantially glidant free levetiracetam compositions, and methods of preparing such compositions are provided. ... 07/19/07 - 20070166371 - Methods of producing films and capsules made from modified carboxymethylcellulose materials Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such ... 07/19/07 - 20070166370 - Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second ... 07/12/07 - 20070160662 - Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules A capsule is formed from a PVA composition by blow moulding. Such capsules can at last provide a viable alternative to gelatin for biodegradable capsules containing a pharmaceutical or consumable or other substance, for example, a detergent. The capsules may contain solid or liquid substances. Blow moulding apparatus suitable for ... 07/12/07 - 20070160661 - Aspirin formulation for cardiovascular health The invention relates generally to an aspirin formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for maintaining cardiovascular health. The aspirin formulation may comprise supplements such as vitamin B6, vitamin B12, folic acid, arginine and garlic. The invention also encompasses methods for ... 07/12/07 - 20070160659 - Stabilized formulations of phosphatidylserine Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in ... 07/05/07 - 20070154541 - Seamless capsule containing water-soluble active substance A seamless capsule containing a water-soluble active substance in which the water-soluble active substance is protected from becoming unstable and a process for producing the same. The seamless capsule includes: content having a water-soluble active substance and an oily compound, a shell covering the content, and an intermediate layer, which ... 07/05/07 - 20070154540 - Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent Disclosed is a novel use of apigenin as a chondroregenerative agent, which has the effects of reducing elevated of cartilage destruction markers including total synovial fluid volume and proteoglycan, total proteins and prostaglandin in a synovial fluid, improving the condition of synovial cells, and regenerating cartilage. Also, the present invention ... 06/28/07 - 20070148228 - Solid oral dosage form containing an enhancer The invention relates to a pharmaceutical composition and oral dosage forms comprising an HDAC inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon ... 06/28/07 - 20070148227 - Physically/molecularly distributed and/or chemically bound medicaments in capsule shells The present invention proposes a design to incorporate medicaments in the capsule shells (body and cap). Medicaments in the cap and body of the capsules may be different. Other medicaments in the form of granules, beads etc. can be filled in the capsules, which may contain medicaments capsule shell. Thus, ... 06/21/07 - 20070141139 - Composition for intestinal delivery The present invention relates to a new composition, use and method for oral administration to a human or an animal of a physiologically active agent comprising neutralizing agents to increase pH in the digestive system to prevent denaturation, inhibitors of digestive enzymes to substantially prevent enzymatic digestion, and at least ... 06/21/07 - 20070141138 - Omega 3 fatty acid formulations The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using ... 06/21/07 - 20070141137 - Stable capsule preparation A capsule in which an unstable active ingredient has been stabilized is obtained by lowering the moisture content of a solid preparation (granules, subtilis, tablets, etc.) containing a chemical unstable to moisture such as an imidazole PPI compound by drying or the like, and then filling in a capsule comprising ... 06/14/07 - 20070134316 - Soft capsule of butylphthalide and a process for preparing the same The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in ... 06/14/07 - 20070134315 - Orally administrable extended release pellet and tablet formulations of a highly water soluble compound Pharmaceutical compositions comprising an extended release formulation of active compounds effective in the treatment of various pathological conditions are provided. More particularly, the invention provides methods of making and using extended release formulations comprising active compounds that present formulation challenges such as short biological half-life, instability, highly water soluble and/or ... 06/07/07 - 20070128272 - Multi-vitamin and mineral supplement A nutritional solid oral dosage form for administering a calcium nutrient with an iron nutrient includes enterically coated particles, granules or pellets containing a calcium nutrient. An iron nutrient is incorporated into an immediate release matrix. The coated calcium nutrient may be located in a core surrounded by the immediate ... 06/07/07 - 20070128271 - Formulation and manufacturing process for calcium acetate capsules The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule. ... 06/07/07 - 20070128270 - Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide and pharmaceutically acceptable additives including at least one surfactant are made. ... 06/07/07 - 20070128269 - Sustained drug release compositions The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release ... 06/07/07 - 20070128268 - Pharmaceutical compositions comprising an antibiotic The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form. ... 06/07/07 - 20070128267 - Blends of gelling and non-gelling starches with gellan gums and plasticizer The present invention relates to a blend of gelling and non-gelling starches with gellan gums and a plasticizer having similar textural and functional properties compared to gelatin. Films prepared using such blends have excellent strength and elongation. The blend can also be used to prepare capsules without heat. The present ... 06/07/07 - 20070128266 - Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders Pharmaceutical and/or dietary compositions for supplying energy and eutrophication factors to the large intestine to improve its functionality and prevent the appearance of pathological conditions are described. The pharmaceutical and/or dietary compositions described are composed of one or more short-chain monocarboxylic acids or their salts, esters and/or amides, mixed with ... 05/31/07 - 20070122470 - New combination dosage form The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present ... 05/24/07 - 20070116756 - Stable pharmaceutical compositions A pharmaceutical dosage form, comprising an outer capsule containing at least one capsule, tablet, and/or particles comprising different drug substances. ... 05/17/07 - 20070110800 - Pharmaceutical composition having uniform drug distribution and potency Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compositions are disclosed. ... 05/17/07 - 20070110799 - Film-forming starchy composition A film-forming starchy composition for the film-coating of solid forms or the preparation of films. The inventive composition has an amylose content of between 25 and 45%, preferably between 30 and 44% and still more preferably between 35 and 40%, the percentages being expressed by dry weight in relation to ... 05/10/07 - 20070104778 - Controlled-release emulsion compositions The present invention is directed to controlled-release composition containing a solubilized material comprising an active agent and at least one oil-based surfactant capable of solubilizing the active agent, the solubilized material dispersed in a controlled-release particulate matrix. ... 05/03/07 - 20070098784 - Delivery system for biological component A controlled release delivery system composition and method applied to humans and animals, for oral, anal or vaginal administration of a biological component is disclosed. Preferably, a bacterium is delivered, and more preferably the bacterium is probiotic in nature, however, the biological component is not limited to the bacterium. ... 05/03/07 - 20070098783 - Hydrophilic vehicle-based dual controlled release matrix system A hydrophilic vehicle-based dual controlled-release matrix system, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a solution or a suspension, which allows for easier formulation of low dose compounds. The matrix includes two rate controlling barriers for the controlled release ... 05/03/07 - 20070098782 - Ramipril formulation A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat. ... 05/03/07 - 20070098781 - Modified release compositions for dpp-iv inhibitors The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor. ... 05/03/07 - 20070098780 - Method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules A method for preparing a pharmaceutical compound by way of magnetic carbon nanocapsules is disclosed. The method comprises steps of: (a) providing a magnetic carbon nanocapsule with C—(COOH)2 group, and Pt cations, to form a complex; (b) collecting the complex from the magnetic carbon nanocapsule; and (c) removing the Pt ... 05/03/07 - 20070098779 - Films and capsules made from modified carboxymethylcellulose materials Films and/or capsules for the delivery of and/or coating of active ingredients are provided. Such edible films and/or capsules comprise particular modified carboxymethylcellulose (CMC) materials either alone or in combination with other types of hydrocolloids or biogums. The utilization of such modified CMC products aids in the production of such ... 05/03/07 - 20070098778 - Co-formulations or kits of bioactive agents Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPARα/γ agonist, PPARγ agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one ... 04/26/07 - 20070092560 - Lipophilic vehicle-based dual controlled release matrix system A lipophilic vehicle-based dual controlled-release matrix, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a suspension, which allows for easier formulation of low dose compounds and/or compounds which are moisture sensitive. The matrix includes two rate controlling barriers for the ... 04/26/07 - 20070092559 - Liquid dosage forms having enteric properties of delayed and then sustained release Pharmaceutical preparations and methods that contain enteric polymers formulated in liquid dosage forms. The preparations and methods provide enteric properties of delayed and then sustained release, without the need for expensive tableting or coating processes. ... 04/19/07 - 20070087049 - Multi-component pharmaceutical dosage form A multi-component pharmaceutical dosage form comprising a plurality of drug substance—containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form. ... 04/19/07 - 20070087048 - Oral dosage combination pharmaceutical packaging A pharmaceutical delivery package comprising fixed unit dose quantities of two or more different active pharmaceutical ingredients (a) combined in a single delivery package, and (b) segregated from one another within said package wherein said package comprises a core containing a first active pharmaceutical ingredient surrounded at least in part ... 04/12/07 - 20070082045 - Seamless capsule manufacturing method, seamless capsule manufacturing device and seamless capsule A seamless capsule manufacturing device comprises a multiple nozzle 7 for ejecting liquid drops into hardening liquid 10 and a flow passage tube 11 for containing hardening liquid 10. The flow passage tube 11 has a deformation section 28 that includes an inlet part 25 and a formation tube part ... 04/12/07 - 20070082044 - Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene The methods of the invention can be used to protect against lymphocyte DNA damage and free-radical associated disorders in a subject. The methods of the present invention can be used to increase the antioxidant capacity in both the aqueous and lipid compartments, decrease DNA oxidation, decrease lipid peroxidation, and increase ... 04/05/07 - 20070077294 - Capsules comprising topiramate Pharmaceutical capsules containing uncoated particles comprising topiramate and an acid-insoluble polymer. ... 04/05/07 - 20070077293 - Film-forming composition suitable for hard capsules and method for preparing the same The present invention relates to a film-forming composition suitable for hard capsules, and a preparation method thereof. More particularly, the invention relates to a film-forming composition for hard capsules, comprising 7-12% by weight of starch, 1-6% by weight of a plasticizer, 0.7-3% by weight of a gelling agent, and 79-91.3% ... 03/29/07 - 20070071808 - Capsule filled with honey Capsules containing honey or other sweeteners that may be added to beverages are described. The capsules may be made from a material that dissolves in water or other fluids, or, alternatively, the capsule may be remain intact in a fluid and provide an edible capsule sweetener. The capsule may contain ... 03/29/07 - 20070071807 - Capsule-type drug-releasing device and capsule-type drug-releasing device system A capsule-type drug-releasing device is capable of freely controlling the release and stoppage of a drug and causing neither the back flow of contents of a stomach, an intestine, or the like nor clogging with the contents. A capsule-type drug-releasing device may include: a capsule-shaped casing; a cation exchange membrane ... 03/29/07 - 20070071806 - Tansmucosal drug delivery system Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in ... 03/22/07 - 20070065502 - Methods and apparatus for sealing capsules Methods and apparatus for providing a leak-proof seal for two-piece capsules containing oil-based liquids or other compositions by a two-stage process. The capsule cap and capsule body are combined by a nitrogen purge instant bonding (NPIB) system. An overlay medium is applied to selected portions of the capsule, including near ... 03/22/07 - 20070065501 - Method for banding hard capsules using hydroxypropylmethyl cellulose (hpmc) as a base The present invention provides a banding composition for hard capsules using hydroxypropylmethyl cellulose (HPMC) as a base comprising (1) low viscosity HPMC; (2) a component selected from the group consisting of methanol, ethanol, isopropanol, 1-propanol, acetone and/or ethyl acetate; (3) a surfactant; and (4) water; and a method for banding ... 03/22/07 - 20070065500 - Northern white kidney bean extract and red kidney bean extract in combination with green tea extract in the treatment of obesity The present invention is for composition containing extract of Northern White Kidney Bean (Phaseolus vulgaris), extract of Red Kidney Bean (Locust Bean Gum) (Ceratonia siliqua) and extract of Green Tea (Camellia Sinensis). This invention as a supplemental compound, aids in weight reduction both in overweight and obese individuals. This invention ... 03/15/07 - 20070059355 - Liquid filled delivery system The present invention provides a delivery system comprising: (a) a container which is a formed body obtained from a film forming composition comprising at least one polysaccharide or polysaccharide derivative; (b) a liquid fill comprising a matrix composition of at least one solvent which is both polar and hygroscopic or ... 03/15/07 - 20070059354 - Sustained release dosage forms of oxcarbazepine This invention relates to a once a day sustained release dosage form suitable for oral administration of oxcarbazepine. The once a day sustained release dosage form of oxcarbazepine includes oxcarbazepine and hydroxypropyl methylcellulose (HPMC) having a viscosity of 11,000 to 25,000 cps. ... 03/01/07 - 20070048365 - Edible coded microsubstrate for pharmaceuticals A system for verifying product authenticity. A verification system may include: coded microstructures contained within a product. In particular implementations, such as pharmaceuticals, the microstructures are edible and, in some cases, even digestible. Glyph coding may be included to enhance the readability of the microstructures that may have been damaged ... 03/01/07 - 20070048364 - Free flowing granules containing carbomer Methods for making granules containing a carbomer whereby the carbomer is mixed with a hot-melt binder that does not lower the glass transition temperature of the carbomer more than 20° C., the binder is subjected to a temperature at which the hot-melt binder melts or becomes tacky, thus binding the ... 03/01/07 - 20070048363 - Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof The invention relates to a pharmaceutical agent, particularly a chemotherapeutical agent, comprising cis-diammoniumdichloro-trans-dihydroxoplatinum(IV) or salts and/or derivatives thereof in the form of capsules, tablets, creams, ointments and infusion solutions, and to the production of said pharmaceutical agent; the invention also relates to the use of such pharmaceutical agents in the ... 02/22/07 - 20070042036 - Fat-soluble drug composition The present invention aims at providing a fat-soluble drug composition having improved absorbability of the fat-soluble component in the living body and being stable as a formulation, specifically a fat-soluble drug composition for capsules. The present invention relates to a fat-soluble drug composition comprising a fat-soluble component and an emulsifier, ... 02/22/07 - 20070042035 - Soft capsule It is an object of the present invention to provide a capsule anti-sticking agent which can provide excellent anti-sticking effect on a soft capsule without impairing various properties such as water activity, disintegration property and safety, a coated soft capsule of high quality which is coated with the capsule anti-sticking ... 02/22/07 - 20070042034 - High drug load formulations and dosage forms The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient. ... 02/22/07 - 20070042033 - Pantoprazole multiparticulate formulations Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a disintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat ... 02/15/07 - 20070036849 - Use of phospholipid arachidonic acids for increasing muscle mass in humans This invention discloses a method of increasing muscle mass comprising administering phospholipid arachidonic acid to a human in need thereof. ... 02/08/07 - 20070031486 - Nutritional supplement for use under physiologically stressful conditions A nutritional supplement to be incorporated into the diet of an individual experiencing physiologically stressful conditions is described. ... 02/08/07 - 20070031485 - Pharmaceutical composition having a cationic excipient The invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier comprising a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. The invention also ... 02/01/07 - 20070026062 - Tablet comprising a fibrate Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state. ... 01/18/07 - 20070014847 - Coated capsules and methods of making and using the same The present invention relates to coated capsules with increased capsule shell pliability and resilience and methods of making the coated capsules. The present invention relates to methods of making coated capsules, the methods comprising applying a coating solution comprising sodium carboxymethylcellulose or sodium alginate to the exterior of a capsule ... 01/18/07 - 20070014846 - Pharmaceutical compositions comprising fenofibrate and atorvastatin Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are ... 01/11/07 - 20070009589 - Extended release compositions Pharmaceutical compositions of metoprolol or a salt have water-insoluble inorganic cores such as dibasic calcium phosphate having the drug deposited thereon, optionally with one or more hydrophilic or hydrophobic polymers or mixtures thereof, and an outer coating of a polymer blend utilizing groups of polymers having opposing wettability characteristics. ... 01/04/07 - 20070003613 - Preparations to support maintenance of acid-alkaline balance in the human body and methods directed to using same The present invention provides novel compositions in the form of a powder, capsule, liquid or lozenge, and methods for administering said novel compositions to assist the body in its ability to maintain a reasonable homeostatic mechanism for compensating for chronic internal acidity. The composition may contain several active ingredients, such ... 01/04/07 - 20070003612 - Capsule A capsule 1 is adapted to be ingestable by a human or an animal and comprises a location determining device 3 for determining the capsule's 1 location following ingestion. ... 01/04/07 - 20070003611 - Novel method of granulating calcium carbonate and products provided therefrom A new and useful method of granulating calcium carbonate is provided. Such a method entails the inclusion of very low amounts of an aqueous solution citric acid to a calcium carbonate material, with subsequent, mixing, drying, milling, and sieving to provide the correct target particle size range for the resultant ... 12/28/06 - 20060292215 - Abscisic acid against cancer Abscisic acid (ABA) a naturally ocurring plant hormone has been identified in this invention with potent properties to fight cancer. ABA is able to produce a hyperpolarization condition on plasma membrane through a decrease of intracellular Na+ and K+. Such phenomenon is produced in cancer cells by mediation of ion ... 12/28/06 - 20060292214 - Nanoparticulate acetaminophen formulations The invention is directed to compositions comprising a nanoparticulate acetaminophen composition, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate acetaminophen particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of aches and pain, and ... 12/28/06 - 20060292213 - Enoximone formulations and their use in the treatment of pde-iii mediated diseases The present invention provides pharmaceutical formulations of the drug enoximone for use in treatment of disease states in which inhibition of PDE-III may be beneficial. ... 12/28/06 - 20060292212 - Use of thickening agents for producing soft capsules and film production method The invention concerns the gelatinization of viscous aqueous or hydroalcoholic liquid components, buffered or not, intended for the production of films for the manufacture of soft capsules. These compositions are notable in particular in that gelatinization thereof is obtained extemporaneously starting with thickening agents that exhibit the unique property of ... 12/21/06 - 20060286163 - Pharmaceutical composition of topiramate The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical ... 12/21/06 - 20060286162 - Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof The present invention relates to an adsorbate, comprising an adsorbent and bicalutamide adsorbed on said adsorbent, a process for preparing same, and a pharmaceutical composition thereof. ... 12/14/06 - 20060280788 - Delivery and formulations of mast cell stabilizers Diseases of the colon are treated by oral ingestion of a unit dosage form containing a mast cell stabilizer as an active agent. The dosage form is targeted for delivery of the active agent to the colon or when in an immediate release formulation, such as a fast-dissolving tablet, powder ... 12/14/06 - 20060280787 - Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof The present invention relates to a pharmaceutical formulation for oral administration of the poorly soluble and therefore hardly bioavailable microtubule polymerization inhibitor Indibulin and a process for its manufacture. In particular, there is provided a pharmaceutical formulation of Indibulin for oral administration comprising a granulate containing micronized Indibulin having a ... 12/07/06 - 20060275360 - Oral dosage forms comprising progesterone and methods of making and using the same The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present ... 12/07/06 - 20060275359 - Palliative effects of morinda citrifolia oil and juice A method of preventing and treating various ailments and diseases by utilizing the Cox-2 selective inhibition characteristics of processed Morinda citrifolia. ... 12/07/06 - 20060275358 - Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme q10 The invention includes dosage formulations, dosage forms and related methods for providing oral dosage forms of low solubility active ingredients such as coenzyme Q1O. The present invention includes a Self-Microemulsifying Drug Delivery System (SMEDDS) in the form of a self-microemulsifying mixture that comprises a combination of a hydrophilic surfactant and ... 12/07/06 - 20060275357 - Organic compounds A solid pharmaceutical composition suitable for oral administration, comprising: (a) S1P receptor agonist; and (b) a sugar alcohol. ... 11/16/06 - 20060257469 - Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of l-dopa decarboxylase It is the embodiment of this invention to form novel compositions of Indoleamines e.g. 5-Hydroxytryptophan (5HTP) and/or Catecholamines e.g. L-Dopa with the gallocatechins e.g. (−)epigallocatechin3-O-gallate (EGCG) and/or (−) epigallocatechin (EGC) or any of the catechins found in green tea in a pharmaceutical or nutritional dosage or dietary regimen be it ... 11/16/06 - 20060257468 - Dietary products comprising one or more of gamma-polyglutamic acid (gamma-pga, h form) and gamma-polyglutamates for use as nutrition supplements The present invention relates to a dietary product comprising γ-polyglutamic acid (γ-PGA, H form), and/or one or more of its salts (i.e., γ-polyglutamate in Na+ form, γ-polyglutamate in K+ form, γ-polyglutamate in NH4+ form, γ-polyglutamate in Mg++ form, and γ-polyglutamate in Ca++ form) for use as a nutrition supplement. ... 11/16/06 - 20060257467 - Compositions and methods for inhibiting gastric acid secretion The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of ... 11/09/06 - 20060251713 - Amino acid sequences capable of facilitating penetration across a biological barrier This invention relates to novel pharmaceutical penetration compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering penetration compositions to affected subjects. ... 11/02/06 - 20060246129 - Composition for use in treatment of sleep problems and method for same The present invention provides a non-addictive composition for the treatment of sleep disorders and problems including melatonin, valerian root extract, an antioxidant component, and a vitamin complex component. The present invention further provides a non-addictive composition for the treatment of sleep disorders and problems including melatonin, valerian Root Extract, proanthocyanidin, ... 11/02/06 - 20060246128 - Micronized tanaproget and compositions containing same The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, povidone, and magnesium stearate. The compositions are useful in contraception and hormone replacement therapy and ... 11/02/06 - 20060246127 - Moulded body made from a gelatine-free material filled with a liquid filling The invention relates to a moulded body, comprising a shell mass made from gelatine-free material and a liquid as filler, whereby the shell mass comprises at least one first biopolymer and at least one plasticiser. At the time of establishment of equilibrium of the water content between the shell mass ... 10/26/06 - 20060240097 - Trpv1 agonist compounds and methods for making and using the same Described here are TRPV1 agonist compounds and their methods of synthesis and use. In addition to specifically identified compounds, capsaicin prodrugs, gemini dimers, and mutual prodrugs are also described. Formulations of the TRPV1 agonist compounds may be in the form of a liquid, tablets, capsules, gel, cream, emulsion, a patch, ... 10/26/06 - 20060240096 - Devices and methods for treating the gastrointestinal system Devices and methods for less invasively treating the gastrointestinal system, such as the intestinal mucosa of the small bowel. Embodiments described herein may be used to reduce caloric absorption and effectuate weight loss, for example. ... 10/26/06 - 20060240095 - Pharmaceutical composition comprising a combination of metformin and a statin A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia, ... 10/26/06 - 20060240094 - Masticatable capsule and process for producing the same This chewable capsule has an encapsulating shell and a filling contained within the encapsulating shell, in which outer diameter of the above encapsulating shell ranges from 14 mm to 25 mm, and mass of the above encapsulating shell ranges from 10% to 20% of the total mass of the chewable ... 10/19/06 - 20060233874 - Seamless capsule A seamless capsule including a filler material and a shell which encapsulates the filler. The shell comprises (a) a shell material and (b) a crystallization agent which is one or two or more selected from a group consisting of sorbitol, mannitol, xylitol, erythritol, paratinitt, lactitol, maltitol, trehalose, and saccharose. The ... 10/19/06 - 20060233873 - Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same The present invention concerns a dispersion of crystals or granules of active substance in a lipophilic vehicle, said crystals or granules being coated by a coating for taste masking purposes. The invention also it concerns unit dosage forms and preferentially chewable or fast dissolving soft gelatin capsules filled with said ... 10/19/06 - 20060233872 - Pharmaceutical product which is used to reduced or stop moderate or severe snoring The invention relates to the novel use of a pharmaceutical product which combines domperidone and pseudoephedrine sulphate substances and which can be used to reduce or stop moderate or severe snoring. ... 10/12/06 - 20060228408 - Drug delivery system An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly ... 10/05/06 - 20060222701 - Compositions with hydrophilic drugs in a hydrophobic medium In various embodiments of the present invention, a capsule is provided including a hydrophobic inner layer and at least one hydrophilic outer layer. The hydrophobic layer may include a hydrophilic component such as an active pharmaceutical ingredient (API) which may be fully encapsulated, partially encapsulated or part of an adsorption ... 10/05/06 - 20060222700 - Tablet and capsule form of liquid active ingredient A tablet includes a liquid active ingredient, such as benzonatate, and a powdered material, such as fumed silica. The powdered material has adsorbed a high proportion by weight of the liquid active ingredient while maintaining characteristics of a solid. The liquid active ingredient and the powdered material are compressed to ... 10/05/06 - 20060222699 - Flavored vegetarian cellulose capsule and methods for producing said capsule. A flavored vegetable starch capsule and the method of manufacture of the flavored capsule is provided. The capsule may comprise (a) from about 95% to about 100% parts by weight of cellulose, such as hydroxymethylcellulose; (b) from about 0.5% to about 5.5% by weight of a suitable hydrogenated saccharide, such ... 09/28/06 - 20060216345 - Oral pharmaceutical composition including paroxetine A stable oral pharmaceutical composition including a therapeutically effective amount of paroxetine or its pharmaceutically acceptable salt and one or more adjuvants that prevent the formation of pink hue upon storage of the composition. The composition can be prepared by aqueous granulation. ... 09/28/06 - 20060216344 - Pharmaceutical compositions and dosage forms of thalidomide Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable stereoisomers, prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating, managing, and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory ... 09/21/06 - 20060210621 - Solid dosage form for providing a dietary supplement Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form. The fucoidan is partially hydrolyzed with acid and heat. The ... 09/21/06 - 20060210620 - Co-precipitated amorphous losartan and dosage forms comprising the same The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the ... 09/14/06 - 20060204567 - Potato proteinase inhibitor ii exhibits activity in elevating fasting plasma cholecystokinin concentrations A method of increasing fasting levels of cholecystokinin in a subject by the administration of potato proteinase inhibitor II is described. A method for extending satiety in a subject with elevated fasting cholecystokinin levels due to treatment is also described, along with a method of identifying subjects likely to respond ... 09/07/06 - 20060198883 - Compositions and methods for the treatment of anorectal disorders Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2−) scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used. ... 08/31/06 - 20060193907 - Ngna compositions and methods of use The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided. ... 08/24/06 - 20060188566 - Nanoparticulate formulations of docetaxel and analogues thereof Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can be used in the treatment of cancer. ... 08/24/06 - 20060188565 - Rapidly bioavailable tablet and capsule formulations of diclofenac The present invention relates to excipients for the production of rapidly bioavailable solid oral dosage forms of diclofenac. In particular, the invention relates to the use of excipients that promote the bioavailability of such formulations, including alkaline buffering agents, gas forming excipients, hygroscopic excipients, water soluble diluents, wetting agents, and ... 08/24/06 - 20060188564 - Cellulose hard capsule enhancing mechanical film strength This invention provides a process for preparing a cellulose capsule enhancing mechanical film strength comprising the steps of: i) preparing a mixed solution of iota-carageenan and agar; ii) adding said mixed solution to an aqueous solution of solubilized cellulose; iii) adding sucrose fatty acid ester, potassium pyrophosphate and glacial acetic ... 08/24/06 - 20060188563 - Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis A medicinal oral preparation to be delivered to the large intestine comprising a core containing a pharmacologically active ingredient, an inner layer containing one or more cationic polymers and an outer layer containing one or more anionic polymers whereby the core is coated, which is designed so that, in a ... 08/17/06 - 20060182796 - Taste masked pharmaceutical compositions A pharmaceutical composition for oral administration containing a pharmaceutically active ingredient coated with an amount of a polymer combination of an enteric polymer and an ammonio methacrylate copolymer to effectively mask the taste of the medicament. In a preferred embodiment, the ratio of the enteric polymer to the ammonio methacrylate ... 08/10/06 - 20060177497 - Gellan gum based oral controlled release dosage forms-a novel platform technology for gastric retention A controlled-release dosage form is described, which comprises a matrix formed of ingredients (a) and (b): (a) gellan gum, and (b) one or more hydrophilic polymers; and further comprising a drug incorporated within said matrix. The invention also describes a method for the preparation of said controlled-release dosage forms. ... 08/10/06 - 20060177496 - Pharmaceutical formulations The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units ... 08/03/06 - 20060172004 - Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin The present invention discloses oral compositions comprising pentagastrin (PG) as an effective diagnostic agent for gastric acid secretion. The composition further comprises one or more agents that preserve the availability of PG in the gastric fluids, so that the biological activity of PG is maintained. The pharmaceutical compositions according to ... 07/27/06 - 20060165777 - Dosage forms contained within a capsule or sachet Provided are pharmaceutical dosage forms within structures such as hollow capsules, gelcaps, or sachets, adapted to allow ingestion of a whole dose or a preferably predetermined fraction of said dose when desired. ... 07/27/06 - 20060165776 - Antidepressant oral pharmaceutical compositions Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its ... 07/27/06 - 20060165775 - Capsule and film-forming composition comprising gum arabic A capsule for oral delivery of a composition comprises 60% to 95% by weight of gum arabic and to the remainder a water-soluble polymer, a hydrocolloid and a plasticizer. The proportion of gum arabic is preferably 70% to 90% by weight of all components. The water-soluble polymer is preferably a ... 07/27/06 - 20060165774 - Non gelatin films with improved barrier properties Non gelatin film materials, e.g. hydroxy propyl methyl cellulose comprise e.g. an additive or additives such as an organic acid, e.g. hydroxy carboxylic acid, which form a barrier composition. The resultant films are safe human consumption and find use as a wall material of an ingestible delivery capsule, e.g. containing ... 07/20/06 - 20060159745 - Probiotic and preservative uses of oil-emulsified probiotic encapsulations An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to ... 07/20/06 - 20060159744 - Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof The present invention relates to timed dual release dosage forms of short acting hypnotics or salts thereof adapted to release the short acting hypnotic over a predetermined time period, according to a profile of dissolution characterized in that it comprises two release pulses, the first being immediate (lasting up to ... 07/20/06 - 20060159743 - Methods of treating non-nociceptive pain states with gastric retentive gabapentin Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of ... 07/20/06 - 20060159742 - Stabilized individually coated ramipril particles, compositions and methods The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation ... 07/20/06 - 20060159741 - Pharmaceutical compositions comprising amoxicillin and clavulanic acid The present invention relates to the formed particles comprising amoxicillin and clavulanic acid, the particles being obtained wet granulation. The invention also relates to the procedure for the preparation of these particles and to the pharmaceutical compositions comprising them. ... 07/13/06 - 20060153911 - Method for preserving reduced coenzyme q10 The present invention has its object to provide a method for stably preserving a capsule containing reduced coenzyme Q10, which is useful as foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc. The present invention relates to a method ... 07/13/06 - 20060153910 - Lowering blood glucose, urea, cholesterol, triglycerides and normalizing homocysteine levels by dietary addition of selected essential amino acids and three vitamins Administration of a dietary supplement consisting of L-Tryptophan (80 mgs), L-Methionine (90 mgs), L-Valine (103 mgs), L-Lysine Monohydrochloride (128 mgs), Vitamin B-12 (0.5 mg), Vitamin B-6 (10 mgs), and Folic Acid (0.4 mg) has been shown to reduce postprandial peak blood glucose, lower urea formation, reduce cholesterol and triglyceride blood ... 07/13/06 - 20060153909 - Hard capsule The present invention is directed to a hard capsule filled with a solution containing an active ingredient, characterized in that the solution contains an inorganic chloride and has a water content (w) of 10<w≦80% and a water activity (a) of 0.50≦a≦0.90, and that the capsule is made of a base ... 07/13/06 - 20060153908 - Spherical pellet formulations A process for preparing spherical pellets comprising (a) a water-soluble active ingredient soluble, freely soluble or very soluble in water; and in particular having a water-solubility of ≧0.5 g/ml; (b) a spheronizing agent; (c) a dry lubricant, said method comprising preparing a mixture of the active ingredient, the spheronising agent, ... 07/06/06 - 20060147517 - Taste masking system for non-plasticizing drugs The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a ... 07/06/06 - 20060147516 - Taste masking system for alprazolam The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and alprazolam in a solvent, granulating using that material or forming layers over a solid support therewith. This ... 07/06/06 - 20060147515 - Bioactive dispersible formulation A composition containing an effective amount of a water-insoluble bioactive agent and two surfactants having different HLB values, the difference between the HLB values of the two surfactants being greater than 5. This invention also relates to a method of prepare such a composition. ... 06/29/06 - 20060141026 - Imprinted paintball and apparatus and method for manufacturing same A gel capsule has embossed surface configurations that form, in relief, an imprinted design over the entire extent of its exterior surface. An apparatus and method for producing and/or manufacturing an imprinted gel ribbon that is useful in forming the gel capsule. The apparatus includes a spreader box and a ... 06/29/06 - 20060141025 - Methods and compositions for delivery of catecholic butanes for treatment of tumors The present invention provides kits, methods and compositions for the treatment of tumor and other proliferative diseases such as tumors. The compositions herein contain a substantially pure preparation of at least one catecholic butane, including, for example, NDGA compounds in a pharmaceutically acceptable carrier or excipient. The catecholic butane such ... 06/29/06 - 20060141024 - Synergistic combination kit of alpha,beta-arteether, sulfadoxin and pyrimethamine for treatment of severe/multi-drug resistant cerebral malaria The present invention relates to a method for preparation of synergistic combination kits of α,β-arteether, sulfadoxin and pyrimethamine for the treatment of severe/multi-drug resistant cerebral malaria. ... 06/29/06 - 20060141023 - Pharmaceutical compositions containing abiguanide-glitazone combination The present invention relates to an orally administered pharmaceutical composition that is a combination of two or more antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agent is present in an immediate release form. ... 06/29/06 - 20060141022 - Soft capsule preparation A soft capsule preparation which comprises a dispersion of (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid in a vegetable oil filled in a soft capsule comprising a shell having a light blocking effect. The soft capsule preparation preferably comprises polyoxyethylene sorbitan monooleate and glycerol monostearate and the like as surfactants. As the vegetable oil, soybean ... 06/22/06 - 20060134190 - Formulations of bisphosphonate drugs with improved bioavailability This invention relates to formulations of bisphosphonates such as alendronate. The formulations taught herein enhance bioavailability of bisphosphonates and reduce esophageal and gastric ulcerations associated with them. Also taught herein are methods of preparing the formulations and their clinical use in the treatment of osteoporosis and other bone diseases. ... 06/08/06 - 20060121106 - Therapeutic system comprising amoxicillin and clavulanic acid The present invention relates to a novel therapeutic system suitable for one or twice daily administration of amoxicillin and clavulanic acid. One part of the dosage is provided by at least one immediate release amoxicillin/clavulanic acid pharmaceutical composition, and the other part of the dosage is provided by at least ... 06/01/06 - 20060115525 - Pharmaceutical compositions The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight ... 06/01/06 - 20060115524 - Method for preparation of an agglomerate using melt agglomeration Melt agglomeration for the preparation of an agglomerated material is performed us-ing a vehicle that can be melted at a suitable temperature, an active compound and silicon dioxide as filler. Using silicon dioxide as a filler in melt agglomeration has the benefit that a high ratio of melt to filler ... 05/25/06 - 20060110443 - Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The ... 05/25/06 - 20060110442 - Coated sherical seamless filled capsules Described is a spherical coated capsule comprising (a) a coating-free capsule having (i) a liquid or viscous core and (ii) a seamless solid shell surrounding this core, and (b) a seamless, solid coating surrounding said coating-free capsule, wherein—the diameter of the coated capsule is in the range of 5-9 mm, ... 05/18/06 - 20060105033 - Dietary composition containing conjugated linoleic acid and calcium for improved health The invention provides a composition for oral administration comprising a mixture of conjugated linoleic acid (CLA), docosahexaenoic acid “DHA”, vitamin E, vitamin C, vitamin B6, vitamin B12, folic acid, and calcium together with a suitable carrier. These compositions are particularly useful as dietary supplements administered to reduce the risk factors ... 05/11/06 - 20060099248 - 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed. ... 05/11/06 - 20060099247 - Liquid, gas and/or vapor phase delivery systems This invention relates generally to liquid, gas and/or vapor phase delivery systems and, more particularly, to delivery systems that incorporate at least one layer, film and/or capsule that produces a liquid, gas and/or vapor phase compound or compounds for use therein. ... 05/11/06 - 20060099246 - Non-gelatin soft capsule system A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for ... 05/11/06 - 20060099245 - Hydrodynamically balancing oral drug delivery system with biphasic release The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. ... 05/04/06 - 20060093663 - Drug delivery system and drug capsule and transmitter used therefore Release control of a drug in a drug capsule existing in a subject is extremely simply and accurately performed. A non-contact type IC chip which generates a voltage on the basis of a release command signal from the outside, and a piezoelectric actuator which is driven by the voltage, are ... 04/27/06 - 20060088588 - Medication administering device and system A suppository method and device for taking or administering “over-the-counter” and prescription including a capsule formed by a dissolvable material and specific quantity of a predetermined medication stored or storable in the capsule and sterilized light-resistant, moisture-proof foil peel-back packet for storage and packaging prior to use, which may be ... 04/27/06 - 20060088587 - Dosage forms having a microreliefed surface and methods and apparatus for their production The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of ... 04/27/06 - 20060088586 - Dosage forms having a microreliefed surface and methods and apparatus for their production The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of ... 04/27/06 - 20060088585 - Dosage forms having a microreliefed surface and methods and apparatus for their production The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of ... 04/20/06 - 20060083783 - Treating metabolic syndrome with fenofibrate A method of treating metabolic syndrome in a human diagnosed with metabolic syndrome by administering a therapeutically effective amount of fenofibrate over a treatment period. The results can include identifying a human as not having clinical metabolic syndrome after treatment, as compared to having metabolic syndrome before treatment. ... 04/06/06 - 20060073200 - Lercanidipine capsules The invention provides a modified release lercanidipine pharmaceutical composition comprising at least one waxy substance and a therapeutically effective amount of lercanidipine, wherein oral administration of the modified release lercanidipine pharmaceutical composition to a patient results in a mean lercanidipine plasma concentration of greater than 0.5 ng/ml for the full ... 03/09/06 - 20060051408 - Microcapsules for stabilization of cosmetic, pharmaceutical or food products Microcapsules for stabilisation of cosmetic, pharmaceutical or food products, of a size smaller than 500 μm, comprising a nucleus of an adsorbent material—natural or modified polysaccharide insoluble in water, or an adsorbent inorganic material—in which are contained the active ingredients and is coated by a polymeric material—natural, modified natural or ... 02/23/06 - 20060039966 - Dosage delivery apparatus for improving user acceptance of oral supplements and medicaments and methods for manufacturing same Disclosed herein are methods for improving user acceptance of an oral dosage form containing an active ingredient for use as a supplement and/or medicament by masking undesirous flavors, odors, tastes, smells, and/or palatability associated with certain active ingredients. A user may be a human and/or animal in need of a ... 02/16/06 - 20060034910 - Pharmaceutical composition for extended release of phenytoin sodium The present invention provides an oral extended release solid pharmaceutical composition of phenytoin sodium or its pharmaceutically acceptable derivative thereof and the process of manufacturing the same the said extended release oral solid pharmaceutical composition comprising of at least one suitable pharmaceutically acceptable excipient alongwith phenytoin sodium. The said extended ... 02/09/06 - 20060029660 - Non-gelatin capsule shell formulation A film-forming hydrocolloid composition comprising kappa carrageenan, iota carrageenan, a bulking agent, plasticizer and water is described. The ratio of bulking agent to total carrageenan is from about 1:1 to 20:1. Kappa carrageenan is present in an amount of less than or equal to 50% by weight of total carrageenan ... 02/09/06 - 20060029659 - Immune dengue plus An immune enhancing blood platelet builder that increases the survival rate of the patient against the duration of the dengue fever virus in the body. ... 01/26/06 - 20060018957 - Pharmaceutical dosage forms including rasagiline Provided are pharmaceutical dosage forms that include rasagiline formulated and fabricated so that release of rasagiline in the stomach is retarded or inhibited. ... 01/12/06 - 20060008520 - Delayed release formulations of 6-mercaptopurine The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an ... 01/05/06 - 20060002998 - Pharmaceutical dosage forms of biguanide-sulfonylurea combinations The present invention relates to orally administered pharmaceutical compositions that include a combination of antidiabetic agents wherein one agent is present in an extended release form and the other agent is present in an immediate release form. For example, in one embodiment the dosage form includes an extended release layer ... 01/05/06 - 20060002997 - Nitrofurantoin controlled release dosage form The present invention generally relates to controlled release dosage forms which provide immediate release and sustained release of nitrofurantoin, and processes for their preparation. The controlled release dosage form includes a sustained release portion and an immediate release portion. The sustained release portion includes nitrofurantoin and one or more pH ... 12/29/05 - 20050287205 - Dietary supplement compositions A dietary supplement composition, dosage forms, and methods of use are provided which comprise an effective amount of at least one compound selected from the group consisting of acetic acid, citric acid, and malic acid; and, at least one carrier selected from the group consisting of a cyclodextrin, a porous ... 12/29/05 - 20050287204 - Nutritional or pharmaceutical compositions for increasing the creatine response of organisms There is provided a nutritional or pharmaceutical composition comprising a protein fraction containing L-serine and an energy metabolism precursor wherein the composition is free of glycine or if glycine is present within the composition, the weight ratio of L-serine: glycine after hydrolysis of the composition is of more than 2.7:1, ... 12/29/05 - 20050287203 - Formulation comprising testosteron undecanoate and castor oil Disclosed is a pharmaceutical formulation in the form of a capsule for oral administration comprising testosterone undecanoate as an active ingredient dissolved in a pharmaceutically acceptable liquid carrier, characterized in that the liquid carrier comprises at least 50% by weight of castor oil. The choice of castor oil as the ... 12/22/05 - 20050281872 - Enhanced compliance antiviral medicaments and methods of manufacture and use Reduced gastrointestinal side effect medicaments for treating viral infection in a patient suffering therefrom are provided comprising at least 500 mg of antiviral compound in an oral dosage form that can be administered in effective total daily dosages of antiviral compound ranging from 1000 mg to 2000 mg. The reduced ... 12/22/05 - 20050281871 - Methods for coating substrates for pharmaceutical uses with a mixture of two film-forming coating agents The invention relates to methods for producing pharmaceuticals or parts of pharmaceuticals or food supplements or parts thereof, by coating substrates with a mixture of two film-forming coating agents that can contain other pharmaceutically standard additives, especially softeners and/or a pharmaceutical active ingredient. ... 12/08/05 - 20050271717 - Pharmaceutical compositions of atorvastatin A unit dosage form comprising atorvastatin or a pharmaceutically acceptable salt thereof, prepared without a granulation step, wherein the measured atorvastatin potency of said dosage form shows a relative standard deviation (RSD) for atorvastatin potency per unit dosage form of not more than about 7.8%, when said unit dosage form ... 12/08/05 - 20050271716 - Preparation containing basic drug The present invention provides a pharmaceutical preparation containing basic physiologically active substance and enteric polymer, which has improvements in releasability of the contained physiologically active substance in intestinal canal. The basic medicine-containing preparation of the present invention comprises one or more electrolytes by which the action of the enteric polymer ... 12/01/05 - 20050266071 - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them The present invention relates to pharmaceutical formulations comprising at least one acid-labile proton pump inhibiting agent and at least one antacid, which have improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, safety, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties. The present invention is directed ... 12/01/05 - 20050266070 - Abuse-resistant hydrocodone compounds The present invention decreases the potential for abuse of opioids, particularly hydrocodone, by covalent modification. The invention provides methods of delivering hydrocodone as conjugates that release the hydrocodone following oral administration while being resistant to abuse by circuitous routes such as intravenous (“shooting”) injection and intranasal administration (“snorting”). Further, hydrocodone ... 12/01/05 - 20050266069 - Stable probiotic microsphere compositions and their methods of preparation The invention relates to viable and stable probiotic formulations for intestinal targeting made of microspheres comprising each a core of one or more probiotic bacteria, microcrystallline cellulose with a degree of polymerization from 165-365 and mean diameter from 45 to 180 μm, a disintegrant and a stabilizer, the core being ... 11/17/05 - 20050255156 - Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents The invention can be summarized as follows. The present invention provides a reverse-micellar delivery system for enhanced absorption of an agent of interest across biological membranes such as the gastro-intestinal tract of mammals. The reverse-micelles comprise at least one ionic amphipathic compound, and at least one polar active agent ionizable ... 11/17/05 - 20050255155 - Modified release cilostazol compositions Pharmaceutical composition comprising a therapeutically effective amount of micronized particles of cilostazol or pharmaceutically acceptable salts or esters thereof, wherein at least about 50% of the micronized cilostazol particles have an effective average particle size of less than about 10 microns is provided. ... 11/10/05 - 20050249801 - Stabilization of solid drug formulations Pharmaceutical formulations and dosage forms are provided having improved stability to moisture-induced degradation when compared with conventional dosage forms, especially tablets. The invention features low compression forms of drugs known to be susceptible to moisture-induced degradation together with excipients, preferably in encapsulated forms. In other embodiments, relatively non-volatile oils can ... 11/10/05 - 20050249800 - System for release in lower gastrointestinal tract A system whereby a substance which is orally taken and to be delivered into the lower digestive tract is selectively delivered into the lower digestive tract. More particularly, a system which makes it possible to surely and quickly deliver the aimed substance to the lower digestive tract without being affected ... 11/10/05 - 20050249799 - Polymeric drug delivery system for hydrophobic drugs An oral delivery system for Class II drugs that have low oral bioavailability due to their insolubility in water and slow dissolution kinetics and method for making such a drug delivery system are disclosed herein. The formulation may be a controlled release or immediate release formulation. The immediate release formulation ... 11/10/05 - 20050249798 - Gastroretentive drug delivery system comprising an extruded hydratable polymer According to the present invention there is provided a pharmaceutical product for retention in the stomach. The product is produced by extrusion. The use of extrusion enables the product to take many useful forms. The product may comprise a sheet of hydratable polymer, the hydrated sheet being of a size ... 11/03/05 - 20050244490 - Dosing methods for beta-d-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy The disclosed invention is a composition for and a method of treating a HIV infection in a host, such as a human, using a single, once a day, oral dose of β-D-D4FC in an enteric-coated tablet. The enterically coated β-D-D4FC increases the amount of the drug that remains in active ... 11/03/05 - 20050244489 - Liquid compositions for soft sustained-release capsules and method for production The invention relates to liquid compositions for production of soft sustained-release capsules. According to the invention, the sustained release of the active agent is obtained by in situ formation of a matrix, more or less consolidated and biodegradable, by physical modification of the capsule contents on coming into contact with ... 10/27/05 - 20050238708 - Sealed capsule including an integrated puncturing mechanism A sealed self-piercing capsule for storing and delivering a substance, such as a medicine, comprises one or more barrier layers forming a sealed chamber for containing the substance. An internal puncturing mechanism is disposed within the capsule chamber for puncturing a barrier layer to release the substance from the chamber. ... 10/06/05 - 20050220867 - Delivery system for active components as part of an edible composition having preselected tensile strength A delivery system for inclusion in an edible composition is formulated to have at least one active component encapsulated within an encapsulating material, whereby the delivery system has a tensile strength suitable for delivering the active component at a desired release rate. ... 10/06/05 - 20050220866 - Novel capsule formulations of etoposide for oral use The present invention relates to self microemulsifying pharmaceutical compositions comprising Etoposide that are encapsulated. The composition comprises (i) a drug phase comprising Etoposide, and a solvent; (ii) a co-solvent and (iii) an emulsifying base comprising a lipid, a surfactant and a stabilizer ... 10/06/05 - 20050220865 - Compressed composition comprising magnesium salt An oral solid compress composition comprising a magnesium salt is provided. The composition provides a rapid dissolution of the magnesium salt, wherein not less than 75% of the magnesium salt dissolves within 45 minutes after placement in hydrochloric acid (0.1 N, 900 mL) as per USP Method <711>. In a ... 10/06/05 - 20050220864 - Pharmaceutical dosage forms having controlled release properties that contain a gabab receptor agonist The present invention relates generally to pharmaceutical dosage forms having controlled release properties that contain a γ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries. ... 10/06/05 - 20050220863 - Pharmaceutical dosage forms having controlled release properties that contain a gabab receptor agonist The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a γ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal ... 10/06/05 - 20050220862 - Compositions with reduced hepatotoxicity Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex ... 10/06/05 - 20050220861 - Colonic release compostion The present invention relates to an improved controlled (preferably delayed) release formulation for delivery of prednisolone sodium metasulphobenzoate. The formulation comprises prednisolone sodium metasulphobenzoate surrounded by a coating comprising glassy amylose, ethyl cellulose and dibutyl sebacate, wherein the ratio of amylose to ethyl cellulose is from (13.5) to (1:4.5) and ... 09/29/05 - 20050214363 - Pharmaceutical compositions and methods of treatment based on diclofenac New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain ... 09/29/05 - 20050214362 - Appetite suppressant A method of suppressing appetite is disclosed. An amount of wheat bran sufficient to suppress appetite is consumed prior to or with a meal to achieve satiety and desirable weight reduction. POSTUM®, a coffee-substitute and containing wheat bran as the quantitatively main ingredient, may be used in one embodiment. It ... 09/29/05 - 20050214361 - Photostabilized soft capsule An object of the present invention is to provide a small-sized light-stabilized soft capsule formulation, which has a shell that ensures effective light-shielding of an active ingredient encapsulated thereby. The present invention provides a light-stabilized soft capsule formulation comprising a shell containing a non-water-soluble light-shielding agent and having an average ... 09/29/05 - 20050214360 - Diclofenac sodium oral pharmaceutical The present invention relates to a diclofenac sodium oral pharmaceutical containing diclofenac sodium, a nonionic surfactant, a cholic acid derivative as an absorption promoting agent, and a glycerin or a glycol. The oral pharmaceutical has a rapid-acting effect and a good internal absorption even under non-fasting condition. Further, the pharmaceutical ... 09/22/05 - 20050208125 - Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances The enol tautomer of 3-indolylpyruvic acid in stable and pure form, as well as alkali and alkali-earth salts thereof are produced by synthesis process. The enol tautomer comprises only the geometric isomer (Z) and it is the only one tautomeric form having relevant pharmacological effects. The compounds obtained exhibited relevant ... 09/22/05 - 20050208124 - Drugs containing riboflavin-type compounds A medicament is provided containing as an active ingredient at least one of riboflavin, a riboflavin derivative or a pharmacologically acceptable salt thereof, which has the action of suppressing IL-1β, IL-6, IL-10, INF-γ, TNF-α, GM-CSF, IL-8, MCP-1 and other cytokines. Moreover, a preventative or therapeutic agent for inflammatory diseases accompanied ... 09/15/05 - 20050202080 - In process conversion method for preparing tannate tablet, capsule or other solid dosage forms The present invention relates generally to the field of tannate chemistry and more specifically to methods for processing tannate tablets, capsules, or other solid dosage forms. The present invention provides a novel manufacturing process for the conversion of one or more active pharmaceutical ingredients (“API”) into their tannate salt complexes ... 09/15/05 - 20050202079 - Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation The present invention relates to a novel orally administrable formulation of nitrofurantoin comprising a first component being a controlled release form, which comprises nitrofurantoin monohydrate, sodium alginate, alginic acid and hypromellose, and a second component being an immediate release form, which comprises macrocrystalline nitrofurantoin. A method for preparing said formulation ... 09/08/05 - 20050196437 - Hard capsules The present invention pertains to a blend of a physically induced starch hydrolysate, a plasticizer, and a gelling agent. Such blend produces an excellent film with low brittleness. Further, essentially gelatin-free hard capsules may be made with such blends. ... 09/08/05 - 20050196436 - Blends of different acyl gellan gums and starch The present invention relates to a method of producing a film forming blend of different acyl gellan gums with starch having similar textural and functional properties compared to gelatin. Films prepared using such blends have a high modulus and excellent strength and elongation. The present invention also relates to soft ... 09/01/05 - 20050191346 - Delivery capsules A delivery capsule, designed to retain and protect its contents until an intended site of delivery or conditions of delivery are encountered, has at least two separate chambers (18, 20), the chambers usually containing different materials. The capsule is preferably internally divided by a dividing wall or septum (16), conveniently ... 08/25/05 - 20050186268 - Hard capsule A method of manufacturing a hard capsule made mainly of a polymer or copolymer obtained includes polymerizing or copolymerizing at least one polymerizable vinyl monomer in the presence of polyvinyl alcohol and/or a derivative thereof. Unlike conventional hard capsules, this hard capsule can be filled with a solvent (e.g., polyethylene ... 08/25/05 - 20050186267 - Capsules containing aqueous fill compositions stabili |